Form 4: Pfizer Executive Sally Susman Reports Acquisition of Stock Appreciation Rights

Executive Vice President Sally Susman reports the acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Summary

• Sally Susman, an Executive Vice President at Pfizer Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of stock appreciation rights (SARs) on February 27, 2024.
• Susman acquired 68,045 SARs that will be settled in Pfizer common stock on February 27, 2029, subject to vesting requirements.
• Additionally, Susman acquired 60,124 SARs that will be settled in Pfizer common stock on February 27, 2031, also subject to vesting requirements.
• The exercise price for both sets of SARs is $26.89.
• Following the reported transactions, Susman directly owns 68,045 and 60,124 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing executive compensation. It is neutral in tone and does not contain information that would significantly impact investor sentiment.

Positives

• The acquisition of SARs by a high-ranking executive could be interpreted as a sign of confidence in the company's future performance.

Future Outlook

The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth and seventh anniversary of the grant date.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. The acquisition of SARs is a common way to incentivize executives to improve company performance.

Comparison to Industry Standards

• Stock appreciation rights are a fairly standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Johnson & Johnson, Merck, and AbbVie also utilize SARs as part of their executive compensation plans.
• The vesting schedules and settlement terms are generally comparable across these companies, with vesting periods typically ranging from 3 to 5 years.

Key Dates